These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 15770691)

  • 1. Coexpression of the type 1 growth factor receptor family members HER-1, HER-2, and HER-3 has a synergistic negative prognostic effect on breast carcinoma survival.
    Wiseman SM; Makretsov N; Nielsen TO; Gilks B; Yorida E; Cheang M; Turbin D; Gelmon K; Huntsman DG
    Cancer; 2005 May; 103(9):1770-7. PubMed ID: 15770691
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tissue microarray-based studies of patients with lymph node negative breast carcinoma show that met expression is associated with worse outcome but is not correlated with epidermal growth factor family receptors.
    Tolgay Ocal I; Dolled-Filhart M; D'Aquila TG; Camp RL; Rimm DL
    Cancer; 2003 Apr; 97(8):1841-8. PubMed ID: 12673709
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical utility of type 1 growth factor receptor expression in colon cancer.
    Leung SP; Griffith OL; Masoudi H; Gown A; Jones S; Phang T; Wiseman SM
    Am J Surg; 2008 May; 195(5):604-10. PubMed ID: 18424279
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic implications of altered human epidermal growth factor receptors (HERs) in gastric carcinomas: HER2 and HER3 are predictors of poor outcome.
    Begnami MD; Fukuda E; Fregnani JH; Nonogaki S; Montagnini AL; da Costa WL; Soares FA
    J Clin Oncol; 2011 Aug; 29(22):3030-6. PubMed ID: 21709195
    [TBL] [Abstract][Full Text] [Related]  

  • 5. EGFR family expression in breast carcinomas. c-erbB-2 and c-erbB-4 receptors have different effects on survival.
    Suo Z; Risberg B; Kalsson MG; Willman K; Tierens A; Skovlund E; Nesland JM
    J Pathol; 2002 Jan; 196(1):17-25. PubMed ID: 11748637
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Flt-4-positive vessel density correlates with vascular endothelial growth factor-d expression, nodal status, and prognosis in breast cancer.
    Nakamura Y; Yasuoka H; Tsujimoto M; Yang Q; Imabun S; Nakahara M; Nakao K; Nakamura M; Mori I; Kakudo K
    Clin Cancer Res; 2003 Nov; 9(14):5313-7. PubMed ID: 14614015
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Correlated expression of erbB-3 with hormone receptor expression and favorable clinical outcome in invasive ductal carcinomas of the breast.
    Lee Y; Cho S; Seo JH; Shin BK; Kim HK; Kim I; Kim A
    Am J Clin Pathol; 2007 Dec; 128(6):1041-9. PubMed ID: 18024331
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Levels of hypoxia-inducible factor-1alpha independently predict prognosis in patients with lymph node negative breast carcinoma.
    Bos R; van der Groep P; Greijer AE; Shvarts A; Meijer S; Pinedo HM; Semenza GL; van Diest PJ; van der Wall E
    Cancer; 2003 Mar; 97(6):1573-81. PubMed ID: 12627523
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Different influence of Her-2 expression on the prognosis in node-positive and node-negative breast cancer].
    Wang Y; Yao L; Liu YQ; Xu Y; Ou YT; Li JF; Wang TF; Fan ZQ; Fan T; Lin BY; Xie YT
    Zhonghua Zhong Liu Za Zhi; 2010 Jul; 32(7):511-4. PubMed ID: 21029694
    [TBL] [Abstract][Full Text] [Related]  

  • 10. beta-Catenin and p53 analyses of a breast carcinoma tissue microarray.
    Chung GG; Zerkowski MP; Ocal IT; Dolled-Filhart M; Kang JY; Psyrri A; Camp RL; Rimm DL
    Cancer; 2004 May; 100(10):2084-92. PubMed ID: 15139049
    [TBL] [Abstract][Full Text] [Related]  

  • 11. LEA-135 expression: its association with a lower risk of recurrence and increased overall survival of patients with lymph node-positive primary invasive breast cancer.
    Saha B; Zhang N; Naritoku WY; Tsao-Wei DD; Groshen SL; Carlsson G; Larsson L; Gustavsson B; Chaiwun B; Taylor CR; Imam SA
    Anticancer Res; 2004; 24(4):2391-400. PubMed ID: 15330189
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of HER-2/neu overexpression with the number of involved axillary lymph nodes in hormone receptor positive breast cancer patients.
    Tokatli F; Altaner S; Uzal C; Ture M; Kocak Z; Uygun K; Bilgi S
    Exp Oncol; 2005 Jun; 27(2):145-9. PubMed ID: 15995634
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic significance of phosphorylated P38 mitogen-activated protein kinase and HER-2 expression in lymph node-positive breast carcinoma.
    Esteva FJ; Sahin AA; Smith TL; Yang Y; Pusztai L; Nahta R; Buchholz TA; Buzdar AU; Hortobagyi GN; Bacus SS
    Cancer; 2004 Feb; 100(3):499-506. PubMed ID: 14745865
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression and co-expression of the members of the epidermal growth factor receptor (EGFR) family in invasive breast carcinoma.
    Abd El-Rehim DM; Pinder SE; Paish CE; Bell JA; Rampaul RS; Blamey RW; Robertson JF; Nicholson RI; Ellis IO
    Br J Cancer; 2004 Oct; 91(8):1532-42. PubMed ID: 15480434
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Survival in patients with brain metastases from breast cancer: the importance of HER-2 status.
    Eichler AF; Kuter I; Ryan P; Schapira L; Younger J; Henson JW
    Cancer; 2008 Jun; 112(11):2359-67. PubMed ID: 18361426
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression and possible prognostic role of MAGE-A4, NY-ESO-1, and HER-2 antigens in women with relapsing invasive ductal breast cancer: retrospective immunohistochemical study.
    Bandić D; Juretić A; Sarcević B; Separović V; Kujundzić-Tiljak M; Hudolin T; Spagnoli GC; Cović D; Samija M
    Croat Med J; 2006 Feb; 47(1):32-41. PubMed ID: 16489695
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Her-2/neu expression in node-negative breast cancer: direct tissue quantitation by computerized image analysis and association of overexpression with increased risk of recurrent disease.
    Press MF; Pike MC; Chazin VR; Hung G; Udove JA; Markowicz M; Danyluk J; Godolphin W; Sliwkowski M; Akita R
    Cancer Res; 1993 Oct; 53(20):4960-70. PubMed ID: 8104689
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Elevated levels of chemokine receptor CXCR4 in HER-2 negative breast cancer specimens predict recurrence.
    Holm NT; Byrnes K; Li BD; Turnage RH; Abreo F; Mathis JM; Chu QD
    J Surg Res; 2007 Jul; 141(1):53-9. PubMed ID: 17574038
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Primary breast cancer phenotypes associated with propensity for central nervous system metastases.
    Tham YL; Sexton K; Kramer R; Hilsenbeck S; Elledge R
    Cancer; 2006 Aug; 107(4):696-704. PubMed ID: 16826579
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Absence of HER4 expression predicts recurrence of ductal carcinoma in situ of the breast.
    Barnes NL; Khavari S; Boland GP; Cramer A; Knox WF; Bundred NJ
    Clin Cancer Res; 2005 Mar; 11(6):2163-8. PubMed ID: 15788662
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.